Because Patients Matter
Make Better-Informed Decisions
Be Ready Against Hereditary Cancer
Helping Children Lead Better Lives
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx™ test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza™ (olaparib). Lynparza is a PARP (poly-ADP ribose polymerase) inhibitor being developed by AstraZeneca.
MORE women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, research shows.
Sciencewerke to Provide Courtagen’s Clinical Testing to Clinicians in Singapore, Malaysia, and Indonesia
WOBURN, MA. May 29, 2014 – Courtagen Life Sciences, Inc., an innovative molecular information company, announced today an international distribution agreement with Sciencewerke Pte Ltd. Sciencewerke is headquartered in Singapore, and has offices in Malaysia and Indonesia. The company anticipates this partnership will serve as a model for similar commercial relationships with leading distributors in markets around the world.
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of a new genetic test, lysoSEEK™, which is focused on early identification of genes associated with potentially treatable lysosomal storage disorders.
A whole-genome sequencing study of families with multiple children with autism spectrum disorder has found that siblings often don’t share ASD-related mutations, the researchers say in Nature Genetics.
SAN ANTONIO, TX—EndoPredict (EP) provides more prognostic information than the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N– patient populations, with the greatest differences between EPclin and RS in patients who were N+. In addition, EPclin identified a group of patients at low risk who may be spared chemotherapy.
Myriad Genetics today announced it has received approval from the US Food and Drug Administration for BRACAnalysis CDx™ as a companion diagnostic for AstraZeneca’s Lynparza™ (olaparib), a new drug for advanced ovarian cancer associated with BRCA genes.
Courtagen added the nucSEEK® Focus Nuclear Mitochondrial Gene Panel and epiSEEK® Focus Epilepsy and Seizure Disorder Panel to the company’s test offerings. The new tests will complement the current nucSEEK® Comprehensive Nuclear Mitochondrial Exome Panel and epiSEEK® Comprehensive Epilepsy and Seizure Disorder Panel, respectively. Physicians will now have more flexibility to choose the most appropriate test for their patient.
Courtagen’s rxSEEK™ Epilepsy drug metabolism test identifies an individual’s susceptibility to adverse effects of AEDs, providing powerful information to physicians in determining an effective course of treatment.
“EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period” in a Large Head-to-Head Breast Cancer Study
EMPATHY-P showed that Prolaris provides valuable clinical information that can help physicians improve healthcare and outcomes for their patients with early prostate cancer,” said Colin Hayward, M.D., European medical director, Myriad. “There is no one-size-fits-all treatment approach in prostate cancer. Prolaris provides objective genetic information to help clinicians tailor treatment plans based on patients’ individual risk profiles.
CDx Lab in Europe
Myriad Genetics announced today that it has established a European laboratory that will offer its Tumor BRACAnalysis CDx test to guide treatment with PARP inhibitors, namely AstraZeneca’s olaparib.
Myriad Genetics, in collaboration with SciencewerkeDX organised a series of talks in Jan 2015 to raise awareness of hereditary cancer.
Our speaker, Karen Copeland is the director of International Medical Affairs, Myriad Genetics GmbH and also a certified genetic counsellor.
The myRisk™ Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.
Personalis introduces the first test to combine an enhanced clinical exome with genome-wide structural variant detection.
Menlo Park, CA – Personalis, Inc., the leading provider of advanced medical exome and genome sequencing and interpretation services today announced the launch of an early access program to the Personalis ACE Clinical Exome™, a single test that integrates enhanced exome sequencing with genome-wide structural variant detection to increase diagnostic yield. “Personalis’ goal is to improve diagnostic yield while decreasing overall cost and turnaround time compared with traditional serial genetic testing. Until now separate testing has been required for exome-wide small variant detection and genome-wide structural variant detection” said Personalis’ CEO John West “Our ACE Clinical Exome replaces this serial genetic testing approach with a single, convenient test”.
Run For Hope is an annual run that aims to raise much-needed awareness and support for cancer research. For their 23rd year running, SciencewerkeDx was privileged to be a part of Run For Hope 2016 as a Gold Sponsor.
Deficits in Children with Autism
Children with autism experience deficits in a type of immune cell that protects the body from infection. Called granulocytes, the cells exhibit one-third the capacity to fight infection and protect the body from invasion compared with the same cells in children who are developing normally.
NEW YORK (GenomeWeb) – A group of experts has recommended that newly diagnosed colorectal cancer patients should receive genetic tests to identify which ones may have Lynch syndrome, the American Gastroenterological Association said today.
Three-person in vitro fertilization is on the way in the UK, and should be ready for use in preventing the birth of children with mitochondrial disease around two years, says a panel tasked with examining the state of this science.
The goal of these procedures is to help women who have mitochondrial diseases have healthy babies.
New cancer tests that sequence only a patient’s tumor and not normal tissue could result in a significant number of false positive results, potentially leading doctors to prescribe treatments that might not work, U.S. researchers said on Wednesday. The issue is that few of these tests look at DNA from healthy cells to compare which mutations patients were born with and which are unique to the cancer, said Dr. Victor Velculescu of Johns Hopkins and a principal in Personal Genome Diagnostics, a company co-founded by the researchers.
Feb 11, 2016 | a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – More young women with breast cancer are undergoing BRCA1 and BRCA2 mutation testing, according to a Dana-Farber Cancer Institute-led team of researchers.
Cancer is a disease of abnormal gene function. Some gene changes that lead to cancer may be inherited. Breast, ovarian, prostate, and colon are some of these cancers that are linked to a family history. The genetic mutations that cause many of the known hereditary cancer syndromes have been identified, and genetic testing can confirm whether a condition is the result of an inherited syndrome. Genetic profiling may help you or other family members in planning health care for the future.
The majority of cardiovascular disease (CVD) is caused by risk factors that can be controlled, treated or modified. However, there are some major CVD risk factors that cannot be controlled. Current risk functions evaluate characteristics which can only be identified once they appear, without considering other potential factors such as the patient’s genetic constitution. Genetic profiling may provide personalized information, enabling cardiovascular risk to be identified in a more precise manner.
Getting your child’s illness diagnosed might feel like a never-ending quest—especially if he or she is suffering from a complicated neurological or metabolic disorder such as mitochondrial disorder, epilepsy and seizure, or neuro- developmental disorder. Multiple lines of evidence support that genetic factors play a pivotal role in the etiology of these disorders. Your child’s unique genetic profile may help shed light on new information that could lead to a more accurate diagnosis and potential treatment options.
Rare genetic disorders can go undiagnosed for years. The lack of a diagnosis can have considerable adverse effects for patients and their families, including failure to identify potential treatments, failure to recognize risk of recurrence in subsequent pregnancies, and failure to provide anticipatory guidance and prognosis. Genetic testing has proven to be effective in detecting rare variants in an individual’s genome, offering hope to individuals with previously undiagnosed or untreated rare disorders.